VINCE CHHABRIA, District Judge.
The defendants' unopposed motion to sever improperly joined plaintiffs is granted, and the contested motion to transfer Spiegel's case is granted.
Transfer under § 1404(a) requires "a lesser showing of inconvenience" than dismissal for forum non conveniens. Norwood v. Kirkpatrick, 349 U.S. 29, 32 (1955). The burden of demonstrating inconvenience falls on the party seeking transfer. Commodity Futures Trading Comm'n v. Savage, 611 F.2d 270, 279 (9th Cir. 1979). In determining whether transfer is appropriate in any particular case, the district court may consider a number of factors, including:
Jones v. GNC Franchising, Inc., 211 F.3d 495, 498-99 (9th Cir. 2000) (footnotes omitted).
The convenience of the witnesses, particularly non-party witnesses, is often the most important factor. See Florens Container v. Cho Yang Shipping, 245 F.Supp.2d 1086, 1092 (N.D. Cal. 2002); see also Saleh v. Titan Corp., 361 F.Supp.2d 1152, 1160 (S.D. Cal. 2005). The Court must also consider the relative importance of the witnesses. See Gates Learjet Corp. v. Jensen, 43 F.2d 1325, 1335-36 (9th Cir. 1984) (explaining, in a forum non conveniens case, that "the court should have examined the materiality and importance of the anticipated witnesses' testimony and then determined their accessibility and convenience to the forum"). And although a plaintiff's choice of forum is generally accorded significant weight, this weight is substantially lessened where the plaintiff does not reside in the forum and the acts that gave rise to the case did not occur in that forum. See Pac. Car & Foundry Co. v. Pence, 403 F.2d 949, 954 (9th Cir. 1968).
Spiegel alleges that she developed peripheral neuropathy as a result of taking Levaquin, and that Levaquin's manufacturer, Defendant Janssen Pharmaceuticals, and a Levaquin distributor, Defendant McKesson Corporation, failed to warn her of that risk. Spiegel is a resident of New York. She does not allege that any events directly related to her injuries took place in California. Spiegel's doctors and all documents related to her medical, pharmacy, insurance, and employment records are located in New York. However, McKesson's principal place of business is within the Northern District of California, and Spiegel argues that, under California law, McKesson's role as a participant in the chain of distribution for Levaquin renders McKesson strictly liable for the alleged failures to warn. Docket No. 35 at 9.
To be sure, the Northern District of California is a convenient forum for McKesson. But the Northern District of California's convenience for McKesson is offset heavily by the inconvenience to important third-party witnesses (and the fact that important documentary evidence is located in Maryland). Assuming that McKesson may indeed be held strictly liable for its role in the distribution of Levaquin, the importance of live testimony at trial from any McKesson witnesses to establish this role pales in comparison to the importance of witnesses such as Spiegel's prescribing physician. And there is no means to compel the attendance of Spiegel's doctors at any trial in the Northern District of California. Particularly given Spiegel's lack of contacts with her chosen forum, the remaining factors don't come close to counterbalancing the above factors that militate in favor of transfer.
Because the Court has granted the defendants' motion to sever Spiegel's and Lampard's claims and to transfer Spiegel's action to the Southern District of New York, Lampard must file, within 21 days of the date of this order, an amended complaint containing allegations specific to his claim only.